The value of biomarker comparisons between autosomal dominant and late-onset Alzheimer disease

JAMA Neurology

Volumn 71, Issue 9, 2014, Pages 1087-1088

  Fleisher, Adam S ^a,b  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; PRESENILIN; TAU PROTEIN;

ALZHEIMER DISEASE; AUTOSOMAL DOMINANT ALZHEIMER DISORDER; AUTOSOMAL DOMINANT DISORDER; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DORSAL ATTENTION NETWORK; EDITORIAL; EXECUTIVE FUNCTION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE MUTATION; GENETIC VARIABILITY; HUMAN; INFLAMMATION; NERVE DEGENERATION; NEUROPATHOLOGY; OBSERVATIONAL STUDY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHENOTYPE; SECONDARY PREVENTION; SENSORIMOTOR FUNCTION; CONNECTOME; FEMALE; MALE; NERVE CELL NETWORK; PROCEDURES;

ALZHEIMER DISEASE; CONNECTOME; FEMALE; HUMANS; MALE; NERVE NET;

EID: 84907512792     PISSN: 21686149     EISSN: 21686157     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.1747     Document Type: Editorial

References (10)

1. Thomas JB, Brier MR, Bateman RJ, et al. Functional connectivity in autosomal dominant and late-onset Alzheimer disease [published online July 28, 2014]. JAMA Neurol. doi:10.1001/jamaneurol.2014.1654.
2. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89-95.
3. Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx. 2004;1(2):189-195.
4. Benzinger TL, Blazey T, Jack CR Jr, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A. 2013;110(47):4502-4509.
5. Reiman EM, Langbaum JB, Fleisher AS, et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis. 2011;26(suppl 3):321-329.
6. Bateman RJ, Xiong C, Benzinger TL, et al Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367(9):795-804.
7. Fleisher AS, Chen K, Quiroz YT, et al. Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurol. 2012;11(12):1057-1065.
8. Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 2012;11(12):1048-1056.
9. Kozauer N, Katz R. Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med. 2013;368(13):1169-1171.
10. Hampel H, Frank R, Broich K, et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov. 2010;9(7):560-574.